Dabigatran
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM) . Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) [1][2].
Product Specifications
CAS Number
211914-51-1
Product Name Alternative
BIBR 953; BIBR 953ZW
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Thrombin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Dabigatran.html
Purity
98.06
Solubility
0.1 M HCl : 12.5 mg/mL (ultrasonic) |DMSO : < 1 mg/mL|H2O : < 0.1 mg/mL
Smiles
N=C(N)C(C=C1)=CC=C1NCC2=NC3=CC(C(N(CCC(O)=O)C4=NC=CC=C4)=O)=CC=C3N2C
Molecular Formula
C25H25N7O3
Molecular Weight
471.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[2]Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45 (9) :1757-66.|[3]Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98 (2) :333-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E-EL-H0818-01 24 Tests
Human C3a (Complement Component 3a) ELISA Kit
Sign In for Pricing
View Details E-EL-H0818-02 48 Tests
Human C3a (Complement Component 3a) ELISA Kit
Sign In for Pricing
View Details E-EL-H0818-03 96 Tests
Human C3a (Complement Component 3a) ELISA Kit
Sign In for Pricing
View Details 